Overall, 4.5% of participants reported using a GLP-1 or GLP-1/GIP medication in the past year for any reason; 2.9% reported using them to support weight loss, with 1.7% using them exclusively for weight loss (i.e. not also for type 2 diabetes or heart disease; Table 1). The gene discussed is GIP; the disease is heart disorder.